Northwest & Ethical Investments L.P. Lowers Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Northwest & Ethical Investments L.P. lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 2.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,854 shares of the life sciences company’s stock after selling 1,808 shares during the period. Northwest & Ethical Investments L.P.’s holdings in Illumina were worth $8,132,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its holdings in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the last quarter. Golden State Wealth Management LLC purchased a new stake in Illumina during the fourth quarter worth about $32,000. Assetmark Inc. increased its holdings in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in Illumina during the fourth quarter worth about $45,000. Finally, TD Private Client Wealth LLC boosted its position in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ILMN. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a research report on Friday, February 28th. Robert W. Baird cut their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, March 5th. Royal Bank of Canada cut their target price on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 12th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group cut their price objective on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Trading Down 0.2 %

Shares of Illumina stock opened at $84.79 on Friday. The firm has a market cap of $13.43 billion, a PE ratio of -11.04, a PEG ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The company has a 50 day simple moving average of $109.19 and a two-hundred day simple moving average of $128.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.